N/A
N=67
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
Parkinson's Disease
Bottom Line
View on ClinicalTrials.gov: NCT01106976 ↗Enrolled (actual)
67
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcome: Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AChE PET Neuroimaging |
0.0238; 0.0226 | 0.0009 sig |
Summary
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
Eligibility Criteria
Inclusion Criteria
- Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria for PD.
- Hoehn and Yahr stages 1-2.5 at initial recruitment in baseline study.
- Absence of dementia confirmed by neuropsychological testing at initial recruitment in baseline study.
Exclusion Criteria
- contra-indication for magnetic resonance study
- Pregnancy or breastfeeding
Data sourced from ClinicalTrials.gov (NCT01106976). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.